Timing of treatment in osteosarcoma: challenges and perspectives – a scoping review

Michael S. Kim¹, Ioanna K. Bolia¹, Brenda Iglesias², Tamara Sharf¹, Sidney I. Roberts¹, Hyunwoo Kang¹, Alexander B. Christ¹* and Lawrence R. Menendez¹

Abstract

Background: The timing of events in the management of osteosarcoma may be critical for patient survivorship; however, the prognostic value of factors such as onset of symptoms or initiation of therapy in these patients has not been studied. This study sought to review the literature reporting treatment of osteosarcoma to determine the utility of event timing as a prognostic indicator. Due to significant heterogeneity in the literature, this study was conducted as a scoping review to assess the current state of the literature, identify strengths and weaknesses in current reporting practices, and to propose avenues for future improvement.

Main body: This review screened 312 peer-reviewed studies of osteosarcoma in any anatomic location published in an English journal for reporting of an event timing metric of any kind in a population of 6 or more. Thirty-seven studies met inclusion/exclusion criteria and were assessed for level of evidence, quality, and event timing metric. Reviewers also collated: publication year, population size, population age, tumor site, tumor type, surgical treatment, and adjuvant medical treatment. Extracted event timing data were further characterized using nine standardized categories to enable systematic analysis. The reporting of event timing in the treatment of osteosarcoma was incomplete and heterogeneous. Only 37 of 312 (11.9%) screened studies reported event timing in any capacity. The period between patient-reported symptom initiation and definitive diagnosis was the most reported (17/37, 45.9%). Symptom duration was the second most reported period (10/37, 27.0%). Event timing was typically reported incidentally and was never rigorously incorporated into data analysis or discussion. No studies considered the impact of event timing on a primary outcome. The six largest studies were assessed in detail to identify pearls for future researchers. Notable shortcomings included the inadequate reporting of the definition of an event timing period and the pooling of patients into poorly defined timing groups.

Conclusions: Inconsistent reporting of event timing in osteosarcoma treatment prevents the development of clinically useful conclusions despite evidence to suggest event timing is a useful prognostic indicator. Consensus guidelines are necessary to improve uniformity and utility in the reporting of event timing.

Keywords: Osteosarcoma, Orthopaedic surgery, Timing, Oncology, Surgery, Chemotherapy, Radiation

Background

Osteosarcoma is a rare bone malignancy with a global incidence under 30,000 individuals per year [1, 2]. Adjuvant chemotherapy has increased five-year survival rates three-fold to over 65%, and surgical advances have made radical resection with limb salvage possible in greater than 90% of cases [3]. Despite the marked improvement in outcomes, low case counts make it challenging...
to recruit sufficient populations to power high-quality studies. Meta-analysis of the studies that have been conducted is also challenging because of highly variable reporting of specific event timing periods [4–8].

Event timing metrics such as the period between symptom presentation and definitive diagnosis or between patient presentation and the initiation of medical treatment are important to compare studies and outcomes and to assess the utility of an event timing period as a prognostic indicator. Accurately quantifying the time from symptom onset or diagnosis to the initiation of treatment is of particular interest given the association of treatment delay with poorer outcomes [4, 9]. There is no consensus on what event timing metrics are critical and how they should be reported.

This scoping review’s primary objective was to describe the reporting of time to the initiation of treatment in osteosarcoma with a focus on statistics quantifying the period prior to presentation and the initiation of therapy. Challenges and limitations identified in the process of conducting this scoping review have elucidated the need for consensus guidelines for event timing metrics to enable the comparison of results across studies, and ultimately, to improve outcomes.

Methods
This study was conducted as a scoping review per Preferred Reporting Items for Systematic Reviews and Meta-Analyses – Scoping Review (PRISMA-ScR) guidelines due to significant heterogeneity among studies reporting event timing in the treatment of osteosarcoma [10]. The Embase, Google Scholar, Medline, PubMed, Scopus, and Web of Science databases, Google Advanced Search, and gray literature were queried for studies reporting event timing in the treatment of osteosarcoma from inception to September 10, 2021. The following search terms were combined by “AND” or “OR” to retrieve potentially eligible articles: “osteosarcoma,” “outcomes,” “timing,” and anatomic site (e.g., “pelvis,” “lower extremity”). A full list of search terms is provided as Additional file 1. Inclusion criteria were (1) full text publication in English, (2) prospective or retrospective primary studies, (3) population equal to or greater than 6 patients, (4) treatment for osteosarcoma, (5) reported time to treatment, (6) complete reporting of data to be extracted. Extracted data included: publication year, level of evidence, population size, population age, tumor site, tumor type, surgical treatment, adjuvant medical treatment, and event timing. Data was compiled in an Excel spreadsheet (Microsoft, Redmond, CA). Overall averages (e.g., symptom duration) were calculated by weighting reported means by study population without regard for level of evidence or study design beyond this study’s inclusion criteria. The reference list of included studies was searched manually for further potentially eligible articles. Two reviewers screened each potentially eligible study by title, abstract, and full text, extracted data, and assessed study quality using the Mixed Methods Appraisal Tool (MMAT) [11]. Time to treatment statistics were classified by nine categories. Discrepancies between reviewers were resolved by a third reviewer. The study identification and screening process is presented in Fig. 1.

Results
The initial literature search yielded 312 studies of which 37 met the inclusion criteria. Inter-rater agreement among two reviewers was high in title and abstract screening (90% agreement), full text screening (90% agreement), and study quality assessment (95% agreement). As demonstrated in Fig. 1, general search engines (e.g., Google Advanced Search) were queried in addition to academic databases or registers. This resulted in 859 records identified. However, none were ultimately included in this review. The majority of records identified through general search engines were duplicates of records identified through academic databases. The 201 reports not retrieved occurred due to a promising search result, which was included in the 859 total records identified, led to an inactive website that continued to be indexed by Google or a report eligible for this study was not available on the website.

In total, 4594 patients (2672 males, 1922 females) were included in this study. Five studies (5/37, 13.5%) accounting for 772 patients (772/4814, 16.0%) did not report age in a manner that could be meta-analyzed. The mean patient age of 4042 patients (4042/4814, 84.0%) was 17.1 years (range 0–90 years). The median population was 40 patients with a range of seven to 2442 patients. Only six studies (6/37, 16.2%) included populations equal to or greater than 121 patients [4–7, 12, 13]. Per American Academy of Orthopedic Surgeons criteria, 20 (20/37, 54.1%) studies were of Level of Evidence IV, 14 studies were Level III (14/37, 37.8%), and 3 studies were Level II (3/37, 8.1%) [14]. Included studies are summarized in Table 1 with additional extracted data available as Additional file 2. Per MMAT criteria, 27 studies (27/37, 73.0%) were of high quality, meeting 100% of the tool’s five criteria. Seven studies (7/37, 18.9%) met 80%. Two studies (2/37, 5.4%) met 60%. One study (1/37, 2.7%) met 40%. MMAT grading is reported fully in Additional file 3.

Event timing categories
Nine event timing periods were defined during the study screening process based on the authors’ identification of common trends in event timing reporting. Thirty-three
studies (33/37, 89.2%) reported event timing using one defined period while five studies (4/37, 10.8%) reported event timing using two defined periods for a total of 41 defined event timing periods reported in 37 studies. The number of times each period was used to report event timing is summarized in Table 2.

Period between patient-reported symptom initiation and initial presentation
Five studies (5/37, 13.5%) including 259 patients (259/4594, 5.6%) reported this period [9, 15–18]. The average period between symptom initiation and initial presentation was 4.4 months with a range of 0 to 48 months. Pain was the most reported symptom reported by 87 patients (87/259, 33.6%). A palpable mass was reported by 44 patients (44/259, 17.0%) and peripheral nerve involvement was reported by 27 patients (27/259, 10.4%). No initiating symptom was specified for 101 patients (101/259, 39.0%).

Period between patient-reported symptom initiation and definitive diagnosis
Seventeen studies (17/37, 45.9%) including 907 patients (907/4594, 19.7%) reported this period [4, 5, 19–33]. The average period between symptom initiation and definitive diagnosis was 1.39 months with a range of 0 to 24 months based on 9 studies (9/17, 52.9%) including 302 patients (302/907, 33.3%) that reported a mean period [20, 23–27, 29–31]. Eight studies (8/17, 47.1%) did not report this period in a manner that could be incorporated in the overall mean. Five studies (5/17, 29.4%) including 110 patients (110/907, 12.1%) reported symptoms on an individual basis [19, 21–23, 28]. Of these patients, 61 (61/110, 55.5%) reported pain, 11 (11/110, 10.0%) reported swelling, nine (9/110, 8.2%) reported neurologic dysfunction, and 3 reported pathologic fracture (3/110, 2.7%). The initiating symptom was not reported for the remaining 26 patients (26/110, 23.6%).

Period between patient-reported symptom initiation and medical therapy initiation
No studies reported this period.

Period between patient-reported symptom initiation and surgical intervention
Two studies (2/37, 5.4%) including 200 patients (200/4594, 4.4%) reported this period [6, 34]. Data was reported inconsistently. One study (166/200, 83.0%) reporting this period as 0–1 month ($n = 37), 2 months ($n = 39)$, and 3 months or more ($n = 55$) [6]. The other study (34/200, 17.0%) reported a mean period of 20 months with a range of 7 days to 10 years [34].
Table 1  Summary of population characteristics and event timing category of included studies

| Study                        | Level of Evidence | Total Population | Male | Female | Mean Age | Minimum Age | Maximum Age | Category |
|------------------------------|-------------------|------------------|------|--------|----------|-------------|-------------|----------|
| Amr et al., 2000             | III               | 23               | 11   | 12     | 18.6     | 6           | 45          | 8        |
| Bacci et al., 2009           | III               | 55               | 34   | 21     | 17.9     | 3           | 40          | 8        |
| Bertoni et al., 2005         | III               | 29               | 12   | 17     | 36       | 15          | 65          | 8        |
| Chou et al., 2000            | III               | 14               | 7    | 7      | Not reported | 7          | 21          | 8        |
| Daecke et al., 2005          | III               | 39               | 18   | 21     | Not reported | 5          | 59          | 2        |
| Daugaard et al., 1987        | III               | 87               | 60   | 27     | Not reported | Not reported | Not reported | 6        |
| Donati et al., 2004          | III               | 60               | 30   | 30     | Not reported | 8          | 66          | 8        |
| Evans et al., 2020           | III               | 2442             | 1472 | 970    | 18       | 13          | 32          | 6        |
| Feng et al., 2013            | III               | 16               | 10   | 6      | 37.1     | 15          | 58          | 2        |
| Fuchs et al., 1998           | II                | 11               | 106  | 64     | Not reported | Not reported | Not reported | 6, 7      |
| Fuchs et al., 2009           | III               | 43               | 29   | 14     | 34.4     | 11          | 66          | 2, 8      |
| Guo et al., 1981             | IV                | 12               | 9    | 3      | Not reported | 13          | 60          | 9        |
| Ham et al., 2000             | II                | 40               | 19   | 21     | Not reported | 13          | 83          | 2, 8      |
| Hu et al., 2010              | III               | 18               | 12   | 6      | 48       | 34          | 65          | 2        |
| Jamshidi et al., 2017        | IV                | 7                | 4    | 3      | 25.1     | 7           | 49          | 8        |
| Kager et al., 2010           | III               | 28               | 16   | 12     | Not reported | 2.2         | 49          | 2        |
| Kozlowski et al., 1988       | IV                | 21               | 11   | 10     | 11.4     | 0.5         | 18          | 9        |
| Lawrence et al., 1993        | IV                | 47               | 23   | 24     | 12       | 4           | 20          | 7        |
| Letaief et al., 2020         | III               | 85               | 53   | 32     | 17       | 1           | 62          | 1, 6      |
| Makley et al., 1988          | III               | 166              | 85   | 81     | Not reported | Not reported | Not reported | 7        |
| Ozaki et al., 2002           | IV                | 22               | 9    | 13     | Not reported | 5           | 55          | 2        |
| Ozaki et al., 2003           | IV                | 67               | 41   | 26     | Not reported | 10          | 63          | 2        |
| Parry et al., 2016           | IV                | 121              | 47   | 74     | 29.3     | 9           | 76          | 2        |
| Pylikkan et al., 1997        | IV                | 36               | 21   | 15     | 28       | 5           | 62          | 2        |
| Rao et al., 1978             | IV                | 8                | 4    | 4      | 58.7     | Not reported | Not reported | 2        |
| Saeter et al., 1991          | IV                | 97               | 64   | 33     | Not reported | 6           | 36          | 2        |
| Sathiya Moorthy and Ali, 2012| IV                | 20               | 11   | 9      | 17.1     | 5           | 48          | 2        |
| Sordillo et al., 1983        | IV                | 48               | 23   | 25     | Not reported | 6           | 80          | 2        |
| Stein, 1975                  | IV                | 46               | 26   | 20     | 26.7     | 5           | 73          | 2        |
| Taylor et al., 1985          | IV                | 336              | 188  | 148    | Not reported | Not reported | Not reported | 2        |
| Thomas et al., 2014          | IV                | 7                | 5    | 2      | 36       | 15          | 54          | 7        |
| Trieb et al., 2013           | III               | 49               | 28   | 21     | 21.8     | 9           | 53          | 6        |
| Tsagozis et al., 2019        | IV                | 256              | 147  | 109    | 20       | 0           | 90          | 2        |
| VandenBuscche et al., 2016   | IV                | 17               | 9    | 8      | 29.2     | 12          | 70          | 2        |
| Zileli et al., 2003          | IV                | 34               | 14   | 20     | 42       | 14          | 71          | 2        |
| Zils et al., 2013            | IV                | 20               | 11   | 9      | 31       | 5           | 58          | 2        |
| Zils et al., 2015            | IV                | 7                | 2    | 5      | 13       | 7           | 16          | 2        |

Period between initial presentation and definitive diagnosis
No studies reported this period.

Period between initial presentation and medical therapy initiation
Two studies (2/37, 5.4%) including 256 patients (256/4594, 5.6%) reported this period [9, 12]. One study (171/256, 66.8%) reported this period incidentally by only enrolling patients who started treatment within three weeks of initial presentation [12]. The other study (85/256, 33.2%) reported a mean period of 27 days with a range of 3 to 85 days [9].

Period between initial presentation and surgical intervention
No studies reported this period.
Symptom duration
Ten studies (10/37, 27.0%) including 559 patients (559/4594, 12.2%) reported this period [13, 31–33, 35–40]. The average period of symptom duration was 9.9 months with a range of 0 to 36 months based on nine studies (9/10, 90.0%) including 536 patients (536/559, 95.9%) that reported a mean period [13, 31–33, 36–40].

Other
Five studies (5/37, 13.5%) including 2566 patients (2566/4594, 55.9%) reported a statistic quantifying time to treatment other than the categories previously listed [7, 8, 41–43]. Two studies including 28 patients (28/2566, 1.1%) reported event timing on an individual basis and in a manner that could not be meta-analyzed [8, 42]. Three other studies including 2538 patients (2538/2566, 98.9%) reported the period between definitive diagnosis and medical therapy initiation and/or surgical intervention [7, 41, 43]. The average period between diagnosis and medical therapy was 21.0 days with a range of 0 to 24.5 days based on two studies (2/5, 40.0%) including 2491 patients (2491/2566, 97.1%) [7, 43]. The average period between diagnosis and surgical intervention was 93.0 days with a range of 35.0 to 98.1 days based on three studies (3/5, 60.0%) including 2566 patients (2566/2566, 100.0%) [7, 41].

Discussion
This scoping review classified event timing statistics as reported in 37 studies by nine categories to identify trends in the reporting of time prior to the initiation of treatment of osteosarcoma. Most screened studies did not report event timing statistics in any form demonstrating the need for consensus guidelines in reporting. The most reported period was the time between patient-reported symptom initiation and definitive diagnosis (45.9%). The second most reported period was the time between patient-reported symptom initiation and initial presentation (13.5%). Tied for the third most reported periods were the time between patient-reported symptom initiation and surgical intervention and the time between initial presentation and the initiation of medical therapy (5.4%). The time between patient-reported symptom initiation and the initiation of medical therapy, the time between initial presentation and definitive diagnosis, and the time between initial presentation and surgical intervention were not reported in any studies. Overall symptom duration was commonly reported as a measure of time to treatment despite the poor and variable definition of its start and end points (27.0%). Other statistics that were not defined prior to this study (i.e., the time between definitive diagnosis and the initiation of medical treatment and the time between definitive diagnosis and surgical intervention) were tied for the second most reported periods (13.5%).

No studies assessed the association of patient-reported initiation of symptoms to definitive diagnosis (Category 2) with outcomes. A study of 121 patients suffering from pelvic osteosarcoma presenting to a single institution over 31 years found that metastases at the time of diagnosis had a significant impact on five-year survival rates, but did not consider whether delay in diagnosis impacted the rate of metastases found at diagnosis [4]. A study of 256 patients suffering from chondroblastic osteosarcoma (COS) who presented to a single institution over 37 years reported a mean duration of symptoms of 16 weeks with an interquartile range of six to 18 (Category 8) [13]. While reporting a high incidence of metastases in COS patients, this study did not consider whether time before definitive diagnosis was a contributing factor to the incidence of metastases at the time of diagnosis and whether either statistic had an impact on prognosis. Despite the intuitive connection between delay and presence of metastases and what metastases mean for prognosis, it is impossible to make conclusions about either event timing categories’ utility as a prognostic tool. Future studies

| Period | Start | End | Reported in Studies |
|--------|-------|-----|---------------------|
| 1      | Patient-reported symptom initiation | Initial presentation | 5 |
| 2      | Patient-reported symptom initiation | Definitive diagnosis | 17 |
| 3      | Patient-reported symptom initiation | Medical therapy initiation | 0 |
| 4      | Patient-reported symptom initiation | Surgical intervention | 2 |
| 5      | Initial presentation | Definitive diagnosis | 0 |
| 6      | Initial presentation | Medical therapy initiation | 2 |
| 7      | Initial presentation | Surgical intervention | 0 |
| 8      | Symptom duration | | 10 |
| 9      | Other | | 5 |
of osteosarcoma treatment should include event timing periods in their assessment of end points.

Many studies reported timing in a manner that was unclear and impossible to incorporate in meta-analysis. A study of 336 patients suffering from osteosarcoma in the extremities presenting to a single institution over 18 years reported the period from patient-reported initiation of symptoms to definitive diagnosis (Category 2) using ranges that prevented meta-analysis: 145 patients presented after 1–2 months of symptoms, 78 patients presented after 3–5 months of symptoms, and 98 patients reported after 6 or more months of symptoms [5]. No statement was made as to whether the reported boundaries are inclusive or exclusive. Another large study reported on 166 children with osteosarcoma of the extremities who presented to the Childrens Cancer Study Group institutions over 15 years and exhibited the same inadequate reporting of event timing (Category 4) using poorly defined ranges [6]. Consensus guidelines would facilitate the reporting of event timing data in a manner that is useful to current readers and to future researchers conducting meta-analysis.

The largest study in this review included 2442 patients suffering from osteosarcoma in the extremities in the National Cancer Database study and reported time from definitive diagnosis to surgery, a period not reported by any other study included in this review (Category 9) [7]. While this is an interesting metric, the time from diagnosis to surgery is most likely a reflection of an institution’s operational capacity and the physicians’ decision whether to perform initial surgery versus treat with neoadjuvant chemotherapy, rather than a useful contributor to prognosis.

None of the included studies used an event timing period as an outcome, nor did they discuss the contribution of event timing periods to prognosis. In every study included in this review, event timing was reported alongside demographic data as a characterization of the population, but not a prognostic contributor to outcomes. The remarkable improvement in outcomes among patients diagnosed with osteosarcoma has largely been attributed to the widespread adoption of adjuvant chemotherapy and improved surgical technique. As the treatment of osteosarcoma is standardized, the potential contribution of event timing to prognosis and its utility as an adjunct to tumor staging in the development of patient-specific treatment plans is critical. Due to the complete absence of consideration of the impact of event timing on prognosis and outcomes in the studies included in this review, it is impossible to draw conclusions about the effect of duration of time to diagnosis and treatment on clinical outcomes and survival rates in patients suffering from osteosarcoma. Intuition suggests that delays in treatment allow tumor progression and the development of metastases, which are known to have a negative impact on outcomes and survival. This review demonstrates the need to further investigate the impact of event timing metrics, particularly those quantifying the periods preceding presentation and the initiation of treatment, on functional outcomes and survival. The development of expert consensus statements, such as those produced based on Delphi questionnaires, [44, 45] may be useful in identifying and defining critical event timing metrics and producing reporting guidelines.

Limitations
This study has some limitations. While conducted systematically, this review may have missed eligible studies. It is possible that some authors did not report event timing data that had been collected in detail due to limitations imposed by the publication process, particularly as event timing was not a primary outcome measure in any included study. Ideally, the literature would have reported event timing in a manner that allowed for the identification of periods critical to treatment optimization and improving outcomes. However, this review was significantly limited by the discrepancies in the reporting of event timing, which resulted in very few of the screened studies being included and the inability to utilize coherent categories of event timing statistics that enabled meta-analysis. Due to the limited number of studies and small populations, this study had expansive inclusion criteria and pooled patients with osteosarcoma regardless of demographics, tumor site, and treatment. This prevented the association of event timing with clinical outcomes in this study. The results of this scoping review elucidate the need for further study of event timing and the development of consensus guidelines in the reporting of event timing to facilitate improvements in the treatment of osteosarcoma.

Conclusions
Event timing in the treatment of osteosarcoma may have an impact on prognosis, outcomes, and survival. However, event timing metrics are currently reported inconsistently and have not been studied rigorously. As a result, it is currently impossible to draw conclusions as to their utility as prognostic markers and further research is required to elucidate their use as a clinical tool and consensus guidelines to make reporting uniform and meta-analyzable should be considered.

Abbreviations
PRISMA-ScR: Preferred Reporting Items for Systematic Reviews and Meta-Analyses – Scoping Review; MMAT: Mixed Methods Appraisal Tool.
Supplementary Information

The online version contains supplementary material available at https://doi.org/10.1186/s12885-022-10061-0.

Additional file 1.
Additional file 2.
Additional file 3.

Acknowledgements
Not applicable.

Authors' contributions
MSK extracted, analyzed, and interpreted data and was the primary author of the manuscript. IK8 analyzed and interpreted data and was a major contributor in writing the manuscript. BI was a major contributor in development of this study and in writing the manuscript. TS extracted and contributed to the analysis and interpretation of data. SIR extracted and contributed to the analysis and interpretation of data. HK was a major contributor in the development of this study. ABC interpreted data and was provided clinical insight in the inception and execution of this study. LRM provided clinical insight in the inception and execution of this study. All authors read and approved the final manuscript.

Funding
This study was not funded by any sources.

Availability of data and materials
The datasets used and/or analysed during the current study are available from the corresponding author on reasonable request and have been provided to the journal as supplementary material.

Declarations

Ethics approval and consent to participate
Not applicable.

Consent for publication
Not applicable.

Competing interests
The authors declare that they have no competing interests.

Author details
1 Department of Orthopaedic Surgery, Keck School of Medicine of USC, 1520 San Pablo St, HSC #2000, Los Angeles, CA 90033, USA. 2 Department of Orthopaedic Surgery, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA.

Received: 14 February 2022 Accepted: 5 September 2022
Published online: 10 September 2022

References
1. Ottaviani G, Jaffe N. The epidemiology of osteosarcoma. Cancer Treat Res. 2009;152:3–13.
2. Valery PC, Laversanne M, Bray F. Bone cancer incidence by morphological subtype: a global assessment. Cancer Causes Control. 2013;26(8):1127–39.
3. Misagh A, Goldin A, Awad M, Kulidjian AA. Osteosarcoma: a comprehensive review. Sicot J. 2018;4:12.
4. Parry MC, Laitinen M, Albergo J, Jeys L, Carter S, Gaston CL, et al. Osteosarcoma of the pelvis. Bone Joint J. 2016;98-b(4):555-563.
5. Taylor WF, Irms JC, Pritchard DJ, Dahlin DC, Gilchrist GS, Edmonson JH. Trends and variability in survival among patients with osteosarcoma: a 7-year update. Mayo Clin Proc. 1985;60(2):91–104.
6. Makley JT, Kralio M, Ertel UI, Fryer CJ, Baum ES, Weetman RM, et al. The relationship of various aspects of surgical management to outcome in childhood nonmetastatic osteosarcoma: a report from the Childrens Cancer study group. J Pediatr Surg. 1988;23(2):146–51.
7. Evans DR, Lazarides AL, Visgauss JD, Somarelli JA, Blazer DG, Brigman BE, et al. Limb salvage versus amputation in patients with osteosarcoma of the extremities: an update in the modern era using the National Cancer Database. BMC Cancer. 2020;20(1):995.
8. Kozlowski K, Azouz EM, Campbell J, Marton D, Morris L, Padowani J, et al. Primary bone tumours of the hand. Report of 21 cases. Pediatr Radiol. 1988;18(2):140–8.
9. Letalief F, Khrouf S, Yahiaoui Y, Hamdi A, Gabisi A, Ayadi M, et al. Prognostic factors in high-grade localized osteosarcoma of the extremities: the Tunisian experience. J Orthop Surg. 2020;28(3):2309499020974501.
10. Page MJ, McKenzie JE, Bossuyt PM, Bouthinon I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021;372:n71.
11. Hong QN, Pluye P, Fabregues S, Bartlett G, Boardman F, Cargo M, et al. Improving the content validity of the mixed methods appraisal tool: a modified e-Delphi study. J Clin Epidemiol. 2019;111:49–59.e41.
12. Fuchs N, Bielack SS, Epler D, Bieling P, Delling G, Kuhl KL, et al. Long-term results of the co-operative German-Austrian-Swiss osteosarcoma study group’s protocol COSS-86 of intensive multidrug chemotherapy and surgery for osteosarcoma of the limbs. Ann Oncol. 1998;9(9):893–900.
13. Tsagkou P, Laitinen MK, Stevenson JD, Jeys LM, Abudu A, Parry MC. Treatment outcome of patients with chondroblastic osteosarcoma of the limbs and pelvis. Bone Joint J. 2019;101-b(6):739-744.
14. Okike K, Kocher MS. Evidence-based Orthopaedics: levels of evidence and guidelines in Orthopaedic surgery. In: 2011.
15. Daugaard S, Sunde LM, Kamby C, Schiødt T, Jensen OM. Ewing’s sarcoma: a retrospective study of prognostic factors and treatment results. Acta Oncol. 1987;26(4):281–7.
16. Donati D, Giacomini S, Gozzi E, Ferrari S, Sangiorgi L, Tienghi A, et al. Osteosarcoma of the pelvis. Eur J Surg Oncol. 2004;30(3):332–40.
17. Jamshidi K, Gvechvian B, Mirzaei A. Florid reactive periostitis of the long bone: a case series of seven patients. J Orthop Sci. 2017;22(3):560–5.
18. Sathiyamoorthy S, Ali SZ. Osteoblastic osteosarcoma: cytomorphological characteristics and differential diagnosis on fine-needle aspiration. Acta Cytol. 2012;56(5):481–6.
19. Hu Y, Xia Q, Ji J, Miao J. One-stage combined posterior and anterior approaches for excising thoracolumbar and lumbar tumors: surgical and oncological outcomes. Spine (Phila Pa 1976). 2010;35(5):590–5.
20. Ruo L, Cheng A, Didolkar MS. Extraskeletal osteosarcoma. Clinicopathological study of eight cases and review of literature. Cancer. 1978;41(4):1488–96.
21. Vandenbussche CJ, Sathiyamoorthy S, Wakely PE Jr, Ali SZ. Chondroblastic osteosarcoma: Cytomorphological characteristics and differential diagnosis on FNA. Cancer Cytopathol. 2016;124(7):493–500.
22. Zils K, Bielack S, Wilhelm M, Werner M, Schwarz R, Windhager R, et al. Osteosarcoma of the mobile spine. Ann Oncol. 2011;22(8):2190–5.
23. Zils K, Klingebiel T, Behnisch W, Mueller HL, Schlegel PG, Fruehwald M, et al. Osteosarcoma in patients with Rothmund-Thomson syndrome. Pediatr Hematol Oncol. 2015;32(1):32–40.
24. Ozaki T, Fliege S, Kevric M, Lindner N, Maas R, Delling G, et al. Osteosarcoma of the pelvis: experience of the cooperative osteosarcoma study group. J Clin Oncol. 2003;21(2):334–41.
25. Ozaki T, Fliege S, Liljenqvist U, Hillmann A, Delling G, Salzer-Kuntschik M, et al. Osteosarcoma of the spine: experience of the cooperative osteosarcoma study group. Cancer. 2002;94(4):1069–77.
26. Pylkkänen L, Aho AJ, Eklof T, Salmi TT, Tuominen J, Viljanto J, et al. Chondroblastic osteosarcoma: a comprehensive review of 100 cases. J Orthop Surg. 2020;28(3):2309499020974501.
29. Kager L, Zoubek A, Dominkus M, Lang S, Bodmer N, Jundt G, et al. Osteosarcoma in very young children: experience of the cooperative osteosarcoma study group. Cancer. 2010;116(22):5316–24.
30. Chow E, Merchant TE, Pappo AJ, Jenkins JJ, Shah AB, Kun LE. Cutaneous and subcutaneous Ewing's sarcoma: an indolent disease. Int J Radiat Oncol Biol Phys. 2000;46(2):433–8.
31. Feng D, Yang X, Liu T, Xiao J, Wu Z, Huang Q, et al. Osteosarcoma of the spine: surgical treatment and outcomes. World J Surg Oncol. 2013;11(1):89.
32. Fuchs B, Hoekzema N, Larson DR, Inwards CY, Sim FH. Osteosarcoma of the pelvis: outcome analysis of surgical treatment. Clin Orthop Relat Res. 2009;467(2):510–8.
33. Daeecke W, Bieback S, Martini AK, Everbeck V, Jurgens H, Kotz R, et al. Osteosarcoma of the hand and forearm: experience of the cooperative osteosarcoma study group. Ann Surg Oncol. 2005;12(4):322–31.
34. Zileli M, Hoscoskun C, Brastianos P, Sabah D. Surgical treatment of primary sacral tumors: complications associated with sacrectomy. Neurosurg Focus. 2003;15(5):E9.
35. Amr SM, El-Mofty AO, Amin SN, Morsy AM, El-Malt OM, Abdel-Aal HA. Reconstruction after resection of tumors around the knee: role of the free vascularized fibular graft. Microsurgery. 2000;20(5):233–31.
36. Bacci G, Bonani S, Balladelli A, Barbieri E, Longhi A, Alberghini M, et al. Treatment of nonmetastatic Ewing’s sarcoma family tumors of the spine and sacrum: the experience from a single institution. Eur Spine J. 2009;18(8):1091–5.
37. Bertoni F, Bacchin P, Staals EL, Davidovitz P. Dedifferentiated parosteal osteosarcoma: the experience of the Rizzoli institute. Cancer. 2005;103(11):2373–82.
38. Guo F, Ding BF. Treatment of bone and soft tissue malignant tumours of the extremities by radical resection: A preliminary report of 12 cases. Arch Orthop Trauma Surg. 1981;98(3):201–8.
39. Ham SJ, Kroon HM, Koops HS, Hoekstra HJ. Osteosarcoma of the pelvis: oncological results of 40 patients registered by The Netherlands Committee on Bone Tumours. Eur J Surg Oncol. 2000;26(1):53–60.
40. Stein JJ. Osteogenic sarcoma (osteosarcoma): results of therapy. AMER J ROENTGENOL. 1975;125(3):607–13.
41. Lawrence JA, Babyn PS, Chan HS, Thomer PS, Pron GE, Krajibich UJ. Extremity osteosarcoma in childhood: prognostic value of radiologic imaging. Radiology. 1993;189(1):43–7.
42. Thomas M, Davies AM, Stirling AJ, Girmer RJ, Grainger M, James SL. Imaging appearances and clinical outcome following sacrectomy and ilio-lumbar reconstruction for sacral neoplasia. Skelet Radiol. 2014;43(2):179–89.
43. Trieb K, Sulzbacher I, Kubista B. Bcl-2 correlates with localization but not outcome in human osteosarcoma. Oncol Lett. 2013;6(2):559–61.
44. Rivara FP, Tennyson R, Mills B, Browd SR, Emery CA, Gioia G, et al. Consensus statement on sports-related concussions in youth sports using a modified Delphi approach. JAMA Pediatr. 2020;174(1):79–85.
45. Diermeier T, Rothrauff BB, Engeset L, Lynch AD, Ayeni OR, Paterno MV, et al. Treatment after anterior cruciate ligament injury: panther symposium ACL treatment consensus group. Knee Surg Sports Traumatol Arthros. 2020;28(8):2390–402.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.